We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+3.98%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$77.4B
AUM Growth
-$741M
(-0.95%)
Cap. Flow
-$676M
Cap. Flow
% of AUM
-0.87%
Top 10 Holdings %
Top 10 Hldgs %
26.17%
Holding
1,421
New
35
Increased
882
Reduced
429
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Philip Morris
PM
|
+$347M |
| 2 |
RTX Corp
RTX
|
+$322M |
| 3 |
Synopsys
SNPS
|
+$228M |
| 4 |
Cadence Design Systems
CDNS
|
+$227M |
| 5 |
Manhattan Associates
MANH
|
+$222M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSMC
TSM
|
+$383M |
| 2 |
Broadcom
AVGO
|
+$320M |
| 3 |
Gilead Sciences
GILD
|
+$281M |
| 4 |
Newmont
NEM
|
+$261M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$238M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.99% |
| 2 | Materials | 26.22% |
| 3 | Healthcare | 8.42% |
| 4 | Industrials | 7.31% |
| 5 | Financials | 5.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Haleon
HLN
$43.1B
| $37.2M | 0.05% |
3,612,443
+103,043
| +3% | +$1.01M |
|
227
Tidewater
TDW
$4.19B
| $37.1M | 0.05% |
878,049
+41,796
| +5% | +$2.08M |
|
228
Strategy Inc
MSTR
$35.7B
| $37M | 0.05% |
128,448
+9,318
| +8% | +$2.96M |
|
229
Sanofi
SNY
$102B
| $36.7M | 0.05% |
662,091
-671
| -0.1% | -$36.3K |
|
230
Sociedad Química y Minera de Chile
SQM
$19.6B
| $36.5M | 0.05% |
919,960
+115,047
| +14% | +$4.61M |
|
231
Teck Resources
TECK
$31.8B
| $36.3M | 0.05% |
995,227
-171,191
| -15% | -$7.1M |
|
232
Novartis
NVS
$291B
| $36M | 0.05% |
323,379
-4,235
| -1% | -$451K |
|
233
Teva Pharmaceuticals
TEVA
$40.1B
| $35.7M | 0.05% |
2,320,892
+705,197
| +44% | +$12.6M |
|
234
Prospect Capital
PSEC
$1.13B
| $35.5M | 0.05% |
8,655,753
+528,136
| +6% | +$2.27M |
|
235
Regeneron Pharmaceuticals
REGN
$78.3B
| $35M | 0.05% |
55,227
-3,306
| -6% | -$2.27M |
|
236
Intuitive Surgical
ISRG
$130B
| $35M | 0.05% |
70,670
+1,135
| +2% | +$628K |
|
237
Centrus Energy
LEU
$3.72B
| $34.9M | 0.05% |
560,984
+236,430
| +73% | +$19.9M |
|
|
SA
238
Seabridge Gold
SA
$2.94B
| $34.7M | 0.04% |
2,972,604
-481,367
| -14% | -$5.71M |
|
239
Valaris
VAL
$5.41B
| $34.4M | 0.04% |
876,873
-50,747
| -5% | -$2.18M |
|
240
Palo Alto Networks
PANW
$299B
| $34.2M | 0.04% |
200,284
+676
| +0.3% | +$125K |
|
241
Weyerhaeuser
WY
$18.6B
| $33.4M | 0.04% |
1,139,010
-23,996
| -2% | -$714K |
|
242
Southern Company
SO
$107B
| $33.3M | 0.04% |
362,625
+15,574
| +4% | +$1.35M |
|
243
Enbridge
ENB
$117B
| $33.2M | 0.04% |
749,295
+32,823
| +5% | +$1.43M |
|
244
Vanguard Total Bond Market
BND
$158B
| $32.9M | 0.04% |
448,289
+295,538
| +193% | +$21.4M |
|
245
AGNC Investment
AGNC
$12.6B
| $32.7M | 0.04% |
3,417,568
+447,784
| +15% | +$4.47M |
|
246
AstraZeneca
AZN
$241B
| $32.6M | 0.04% |
221,468
-8,312
| -4% | -$1.2M |
|
247
Oceaneering
OII
$5.02B
| $32.4M | 0.04% |
1,483,304
-85,177
| -5% | -$2.02M |
|
248
Takeda Pharmaceutical
TAK
$52.9B
| $32.3M | 0.04% |
2,172,384
-38,044
| -2% | -$533K |
|
249
GSK
GSK
$103B
| $31.4M | 0.04% |
809,665
-34,374
| -4% | -$1.26M |
|
250
Duke Energy
DUK
$96.9B
| $31.1M | 0.04% |
255,090
+14,996
| +6% | +$1.71M |
|
Similar funds
VanEck Associates's Q1 2025 Portfolio in Review
As of Q1 2025, VanEck Associates held 1,421 positions worth $77.4B, down 0.95% from $78.1B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Trading was light in Q1 2025: portfolio turnover was 4.5%. VanEck Associates opened 35 new positions and exited 29, leaving the 1,421-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 37% of assets, down from 41% a quarter earlier, followed by Materials and Healthcare.
- VanEck Associates's largest Q1 2025 buy was Philip Morris: 2,449,251 shares worth $389M.
- VanEck Associates added most to RTX Corp in Q1 2025, an estimated $322M increase.
- VanEck Associates's biggest Q1 2025 reduction was TSMC, cutting an estimated $383M.
- VanEck Associates fully exited Celestica in Q1 2025, selling an estimated $9.19M.
- VanEck Associates's ten largest holdings make up 26% of its $77.4B portfolio in Q1 2025.
- VanEck Associates opened 35 new positions and closed 29 in Q1 2025.
- VanEck Associates's portfolio value fell 0.95% quarter-over-quarter to $77.4B.
Based on VanEck Associates's 13F filing for Q1 2025, filed 15 May 2025.